Ginkgo bioworks and xprescheck expand cdc's traveler-based genomic surveillance program to detect influenza variants

The program is an effective early warning system for viral variants, leveraging voluntary sampling from international travelers at major u.s. airports boston and new york , jan. 17, 2023 /prnewswire/ -- ginkgo bioworks (nyse: dna) and xwell, inc. (nasdaq: xwel) today announced that they have expanded their support for the centers for disease control and prevention's (cdc's) traveler-based genomic surveillance program to include a pilot study monitoring influenza viruses in addition to sars-cov-2. the partners continue to grow the program's capabilities to provide an additional source of viral surveillance to inform the selection of influenza vaccine viruses for the forthcoming 2023-2024 flu season.
DNA Ratings Summary
DNA Quant Ranking